Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 66 citing articles:

GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 274
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 195
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 104
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 95
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Sofie Hædersdal, Andreas Andersen, Filip K. Knop, et al.
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 6, pp. 321-335
Closed Access | Times Cited: 76
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan, et al.
Nature Metabolism (2024) Vol. 6, Iss. 2, pp. 290-303
Open Access | Times Cited: 67
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Glucagon‐like peptide agonists: A prospective review
Zamara Mariam, Sarfaraz K. Niazi
Endocrinology Diabetes & Metabolism (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 23
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 7
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
David C. D. Hope, Matthew L. Vincent, Tricia Tan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 60
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
Linong Ji, Leili Gao, Hongwei� Jiang, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101691-101691
Open Access | Times Cited: 47
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
Yupeng Liu, Binye Ruan, Huinan Jiang, et al.
American Journal of Clinical Nutrition (2023) Vol. 118, Iss. 3, pp. 614-626
Open Access | Times Cited: 37
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Linong Ji, Hongwei� Jiang, Zhi-Feng Cheng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
Molecular Metabolism (2023) Vol. 78, pp. 101801-101801
Open Access | Times Cited: 24
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2001-2016
Closed Access | Times Cited: 11
Incretin-based investigational therapies for the treatment of MASLD/MASH
Bram Brouwers, Girish S. Rao, Yuanyuan Tang, et al.
Diabetes Research and Clinical Practice (2024) Vol. 211, pp. 111675-111675
Open Access | Times Cited: 11
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li, Guanzheng Yu, Huang Qi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116150-116150
Open Access | Times Cited: 10
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top